Jared Whitlock / endpoints - Grail on Thursday announced that its CEO, Bob Ragusa, will retire and is handing the reins to its current president Josh Ofman. The cancer screening company said the move was the culmination of long-term succession ...
AI Summary: Grail announced a leadership transition as long‑time chief executive Bob Ragusa retires and hands operational control to current president Josh Ofman. The move marks a new chapter for the cancer‑screening company as stakeholders watch for strategic shifts and commentary about the company’s unusual corporate journey and future direction.
Ultra‑sensitive ctDNA blood test could personalize breast cancer care for older women / 2 months
FDA clears blood test to guide breast cancer therapy choices / 22 days
Liquid biopsy may speed childhood Burkitt lymphoma diagnosis in Africa / 2 months
Cancer Grand Challenges awards five teams bold funding for cancer research / 2 months
Two high‑dose radiotherapy sessions safely treat localized prostate cancer / 11 days
Grail’s Galleri blood test misses UK study goal; investor jitters / 3 months
Bristol Myers and Hengrui strike up to $15.2B global oncology pact / 16 days
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.